Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polymerized Dermatophagoides pteronyssinus + Dermatophagoides farinae allergen extract
- Development stage
- Unknown
- Lead developer
- Inmunotek
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
BELTAVAC is a subcutaneous allergen immunotherapy (SCIT) product consisting of polymerized allergen extracts from the house dust mites *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*. Developed by Inmunotek, the extracts are chemically modified using glutaraldehyde to form allergoids. This polymerization process reduces the allergenicity of the extract, thereby enhancing safety and allowing for higher doses, while preserving the immunogenic properties necessary to induce immune tolerance. The drug is indicated for the treatment of allergic rhinitis, allergic rhinoconjunctivitis, and asthma in patients sensitized to house dust mites. It works by modulating the human immune system, specifically shifting the immune response away from IgE-mediated allergic reactions toward a more tolerant state, often characterized by the induction of allergen-specific IgG4 antibodies.
- Brand names
- BELTAVAC
- Other names
- polymerized mite allergen extractmite allergoidglutaraldehyde-modified house dust mite allergen extract
02
Targets
House dust mite allergen-specific CD4+ T-cell receptorHDM-specific IgE (House dust mite-specific immunoglobulin E)
Beyond the preview
Go deeper on polymerized Dermatophagoides pteronyssinus + Dermatophagoides farinae allergen extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polymerized Dermatophagoides pteronyssinus + Dermatophagoides farinae allergen extract.